Acquiring Company
Merck
Acquired Company
Verona Pharma
Pembroke Pines
LondonManufacturingHealthcareBiotechnology ResearchDescription
Merck has strengthened its pipeline through the 2025 acquisition of Verona Pharma, which adds the COPD drug Ohtuvayre. Additionally, recent buyouts of Cidara Therapeutics and Terns Pharmaceuticals have enriched Merck's late-stage influenza and hematology/cancer portfolio. This strategy is part of Merck's efforts to diversify its offerings leading up to the Keytruda patent expiration in 2028.
Don't miss Merck's next move
Get an email the moment Merck makes an acquisition, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Verona Pharma?
Verona Pharma was acquired by Merck, based in Pembroke Pines. The deal was reported on August 21, 2026. Merck is privately held and operates in Manufacturing.
When did Merck acquire Verona Pharma?
Merck's acquisition of Verona Pharma was reported on August 21, 2026. Merck has strengthened its pipeline through the 2025 acquisition of Verona Pharma, which adds the COPD drug Ohtuvayre. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Verona Pharma do?
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for respiratory diseases. It is privately held, operating in Biotechnology Research, and is based in London.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.